Papillary serous cystadenocarcinoma

Summary

Papillary serous cystadenocarcinoma (MONDO:0002368) is a disease and 2 clinical trials. Top therapeutic interventions include selumetinib, trametinib, and letrozole. A subtype of papillary cystadenocarcinoma — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Clinical trials: 2

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	papillary serous cystadenocarcinoma
Mondo ID	MONDO:0002368
DOID	DOID:2632
NCIT	C8377
SNOMED CT	716649003
UMLS	C3839184
MedGen	825029
Is cancer (heuristic)	no

Also known as: micropapillary serous carcinoma · papillary serous adenocarcinoma · papillary serous carcinoma · papillary serous cystadenocarcinoma · serous surface papillary carcinoma (morphologic abnormality)

Disease family

Classification path: human disease › disease by etiologic mechanism › cancer or benign tumor › neoplastic disease or syndrome › neoplasm › cancer › carcinoma › adenocarcinoma › papillary adenocarcinoma › papillary cystadenocarcinoma › papillary serous cystadenocarcinoma

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 2.

Phase distribution (across all retrieved trials)

Phase	Trials
PHASE2/PHASE3	1
PHASE2	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT02101788	PHASE2/PHASE3	COMPLETED	Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer
NCT00551070	PHASE2	COMPLETED	Selumetinib Sulfate in Treating Woman With Recurrent Low-Grade Ovarian Cancer or Peritoneum Cancer

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
SELUMETINIB	4	2
TRAMETINIB	4	2
LETROZOLE	4	1
TOPOTECAN	4	1
CHEMBL4463209	0	1